Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C

Claudio Pasquinelli, Fiona McPhee, Timothy Eley, Criselda Villegas, Katrina Sandy, Pamela Sheridan, Anna Persson, Shu Pang Huang, Dennis Hernandez, Amy K. Sheaffer, Paul Scola, Thomas Marbury, Eric Lawitz, Ronald Goldwater, Maribel Rodriguez-Torres, Michael DeMicco, David Wright, Michael Charlton, Walter K. Kraft, Juan Carlos Lopez-Talavera & 1 others Dennis M. Grasela

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single-and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.

Original languageEnglish (US)
Pages (from-to)1838-1844
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Chronic Hepatitis C
Protease Inhibitors
Hepacivirus
Placebos
Healthy Volunteers
Ribavirin
Virus Diseases
RNA
Interferon-alpha
Genotype
asunaprevir
Antiviral Agents
Headache
Diarrhea
Safety
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. / Pasquinelli, Claudio; McPhee, Fiona; Eley, Timothy; Villegas, Criselda; Sandy, Katrina; Sheridan, Pamela; Persson, Anna; Huang, Shu Pang; Hernandez, Dennis; Sheaffer, Amy K.; Scola, Paul; Marbury, Thomas; Lawitz, Eric; Goldwater, Ronald; Rodriguez-Torres, Maribel; DeMicco, Michael; Wright, David; Charlton, Michael; Kraft, Walter K.; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 4, 04.2012, p. 1838-1844.

Research output: Contribution to journalArticle

Pasquinelli, C, McPhee, F, Eley, T, Villegas, C, Sandy, K, Sheridan, P, Persson, A, Huang, SP, Hernandez, D, Sheaffer, AK, Scola, P, Marbury, T, Lawitz, E, Goldwater, R, Rodriguez-Torres, M, DeMicco, M, Wright, D, Charlton, M, Kraft, WK, Lopez-Talavera, JC & Grasela, DM 2012, 'Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C', Antimicrobial Agents and Chemotherapy, vol. 56, no. 4, pp. 1838-1844. https://doi.org/10.1128/AAC.05854-11
Pasquinelli, Claudio ; McPhee, Fiona ; Eley, Timothy ; Villegas, Criselda ; Sandy, Katrina ; Sheridan, Pamela ; Persson, Anna ; Huang, Shu Pang ; Hernandez, Dennis ; Sheaffer, Amy K. ; Scola, Paul ; Marbury, Thomas ; Lawitz, Eric ; Goldwater, Ronald ; Rodriguez-Torres, Maribel ; DeMicco, Michael ; Wright, David ; Charlton, Michael ; Kraft, Walter K. ; Lopez-Talavera, Juan Carlos ; Grasela, Dennis M. / Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 4. pp. 1838-1844.
@article{1bf9bd8c19e345cfaf69d9116281e5a2,
title = "Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C",
abstract = "Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single-and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.",
author = "Claudio Pasquinelli and Fiona McPhee and Timothy Eley and Criselda Villegas and Katrina Sandy and Pamela Sheridan and Anna Persson and Huang, {Shu Pang} and Dennis Hernandez and Sheaffer, {Amy K.} and Paul Scola and Thomas Marbury and Eric Lawitz and Ronald Goldwater and Maribel Rodriguez-Torres and Michael DeMicco and David Wright and Michael Charlton and Kraft, {Walter K.} and Lopez-Talavera, {Juan Carlos} and Grasela, {Dennis M.}",
year = "2012",
month = "4",
doi = "10.1128/AAC.05854-11",
language = "English (US)",
volume = "56",
pages = "1838--1844",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C

AU - Pasquinelli, Claudio

AU - McPhee, Fiona

AU - Eley, Timothy

AU - Villegas, Criselda

AU - Sandy, Katrina

AU - Sheridan, Pamela

AU - Persson, Anna

AU - Huang, Shu Pang

AU - Hernandez, Dennis

AU - Sheaffer, Amy K.

AU - Scola, Paul

AU - Marbury, Thomas

AU - Lawitz, Eric

AU - Goldwater, Ronald

AU - Rodriguez-Torres, Maribel

AU - DeMicco, Michael

AU - Wright, David

AU - Charlton, Michael

AU - Kraft, Walter K.

AU - Lopez-Talavera, Juan Carlos

AU - Grasela, Dennis M.

PY - 2012/4

Y1 - 2012/4

N2 - Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single-and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.

AB - Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single-and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV.

UR - http://www.scopus.com/inward/record.url?scp=84863337829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863337829&partnerID=8YFLogxK

U2 - 10.1128/AAC.05854-11

DO - 10.1128/AAC.05854-11

M3 - Article

VL - 56

SP - 1838

EP - 1844

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -